Moderate to severe cancer pain and severe pain which does not respond to non-opioid analgesics. TRANSTEC ® is not suitable for the treatment of acute pain.
FDA has accepted for review the resubmitted new drug application for the transdermal sumatriptan migraine patch NP101 fom NuPathe. The...
Alvogen has launched the first generic equivalent of Exelon patch (rivastigmine transdermal system) in the United States. The product will...
Studies of IQP-0410, from ImQuest Biosciences, a promising HIV therapeutic, demonstrate that it can be applied to the skin of...
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., has announced the FDA approved Secuado (asenapine) transdermal system,...
The FDA is investigating the risk of serious burns and potential permanent scarring with the use of Zecuity (sumatriptan iontophoretic...
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has received EC approval for Sancuso (granisteron transdermal patch0 in Europe. Sancuso is...